Acacia Pharma is a commercial stage biopharmaceutical company focused on developing and commercializing novel products to improve the care of patients undergoing serious medical treatments such as surgery, invasive procedures, or chemotherapy.
The Company has identified important and commercially attractive unmet needs in these areas that its product portfolio aims to address. Acacia Pharma's portfolio comprises:
Acacia Pharma has its own commercial infrastructure in the US through which it will sell its products directly.
Acacia Pharma intends to establish licensing and/or distribution agreements with selected pharmaceutical partners outside the US for BARHEMSYS® and APD403.
The Company’s management team and Board have extensive experience in the development and commercialization of hospital pharmaceutical products.
Acacia Pharma was founded in 2007 and has offices in Cambridge, UK and Indianapolis, IN, USA.